Sonoma Bio Co-Founder and Chief Executive Officer Jeffrey Bluestone, Ph.D., Receives Top Scientific Honors

Sonoma Biotherapeutics is proud to announce that Co-founder and CEO Jeffrey Bluestone, Ph.D., has received top accolades from the American Association for the Advancement of Science (AAAS) and the American Association of Immunologists (AAI). Dr. Bluestone has been named a lifetime AAAS Fellow, among the highest honors in the scientific community, as well as recipient of the 2022 AAI-Steinman Award for Human Immunology Research.

AAAS, the world’s largest general scientific society and publisher of the Science family of journals, elected Dr. Bluestone to its newest class of AAAS Fellows, for distinguished contributions to the field of immunology and medicine, particularly regarding understanding of peripheral immune tolerance mechanisms that have major implications in transplantation and autoimmune disease. The 2021 class of AAAS Fellows includes 564 scientists, engineers and innovators spanning 24 scientific disciplines who are being recognized for their scientifically and socially distinguished achievements.

AAI, the nation’s largest professional association of research scientists and physicians who study the immune system, selected Dr. Bluestone as the 2022 recipient of the AAI-Steinman Award for Human Immunology Research. This award recognizes individuals who have made significant, sustained contributions to the understanding of immune processes underlying human disease pathogenesis, prevention, or therapy.

“I am honored to be elected to this year’s class of AAAS Fellows alongside such an accomplished group of scientists and to be recognized by my peers in the immunology community for this prestigious AAI award,” said Dr. Bluestone. “My career has been dedicated to finding the underlying causes of immune-mediated diseases with a goal of developing new immunotherapies to rebalance the immune system and develop tolerance. I’m proud to continue advancing the field through Sonoma Bio’s pioneering work to develop transformative cell therapies for patients with autoimmune and inflammatory disease.”